214 related articles for article (PubMed ID: 35745475)
1. Bactericidal Activity of Ceragenin in Combination with Ceftazidime, Levofloxacin, Co-Trimoxazole, and Colistin against the Opportunistic Pathogen
Paprocka P; Mańkowska A; Skłodowski K; Król G; Wollny T; Lesiak A; Głuszek K; Savage PB; Durnaś B; Bucki R
Pathogens; 2022 May; 11(6):. PubMed ID: 35745475
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of CSA-131 and CSA-131 poloxamer form for the treatment of Stenotrophomonas maltophilia infections in cystic fibrosis.
Oyardi Ö; Savage PB; Erturan Z; Bozkurt-Guzel C
J Antimicrob Chemother; 2021 Jan; 76(2):443-450. PubMed ID: 33094334
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Synergism of Colistin and N-acetylcysteine against
Ciacci N; Boncompagni S; Valzano F; Cariani L; Aliberti S; Blasi F; Pollini S; Rossolini GM; Pallecchi L
Antibiotics (Basel); 2019 Jul; 8(3):. PubMed ID: 31349560
[No Abstract] [Full Text] [Related]
4. Effect of antimicrobials on
Santos Carvalhais BE; Souza E Silva C; Dos Santos KV
Future Microbiol; 2021 Jan; 16(2):83-93. PubMed ID: 33470844
[No Abstract] [Full Text] [Related]
5. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
Wei C; Ni W; Cai X; Zhao J; Cui J
PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial and Antibiofilm Activities of Ceragenins against
Bozkurt Güzel Ç; Hacioğlu M; Inci G; Savage PB
Turk J Pharm Sci; 2019 Dec; 16(4):444-449. PubMed ID: 32454748
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB
J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423
[TBL] [Abstract][Full Text] [Related]
8. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
[TBL] [Abstract][Full Text] [Related]
9. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime.
Di Bonaventura G; Spedicato I; D'Antonio D; Robuffo I; Piccolomini R
Antimicrob Agents Chemother; 2004 Jan; 48(1):151-60. PubMed ID: 14693533
[TBL] [Abstract][Full Text] [Related]
10. [Investigation of the presence of class 1, 2, 3 integrons and their relationships with antibiotic resistance in clinical Stenotrophomonas maltophilia isolates].
Usta E; Eroğlu C; Yanık K; Karadağ A; Güney AK; Günaydın M
Mikrobiyol Bul; 2015 Jan; 49(1):35-46. PubMed ID: 25706729
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review.
Falagas ME; Valkimadi PE; Huang YT; Matthaiou DK; Hsueh PR
J Antimicrob Chemother; 2008 Nov; 62(5):889-94. PubMed ID: 18662945
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care centre in Hungary.
Juhász E; Pongrácz J; Iván M; Kristóf K
Acta Microbiol Immunol Hung; 2015 Sep; 62(3):295-305. PubMed ID: 26551572
[TBL] [Abstract][Full Text] [Related]
13. Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan.
Wu RX; Yu CM; Hsu ST; Wang CH
J Microbiol Immunol Infect; 2022 Feb; 55(1):107-113. PubMed ID: 33500210
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients.
Wang CH; Yu CM; Hsu ST; Wu RX
J Hosp Infect; 2020 Jan; 104(1):46-52. PubMed ID: 31505224
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression.
Pompilio A; Crocetta V; Verginelli F; Di Bonaventura G
FEMS Microbiol Lett; 2016 Jul; 363(14):. PubMed ID: 27242375
[TBL] [Abstract][Full Text] [Related]
16. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
[No Abstract] [Full Text] [Related]
17. Molecular epidemiology and characteristics of 16 cases with Stenotrophomonas maltophilia bacteraemia in pediatric Intensive Care Units.
Motamedifar M; Heidari H; Yasemi M; Sedigh Ebrahim-Saraie H
Ann Ig; 2017; 29(4):264-272. PubMed ID: 28569336
[TBL] [Abstract][Full Text] [Related]
18. Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Chong SY; Lee K; Chung HS; Hong SG; Suh Y; Chong Y
Microb Drug Resist; 2017 Mar; 23(2):163-168. PubMed ID: 27294684
[TBL] [Abstract][Full Text] [Related]
19.
Su BA; Chen CC; Chen HJ; Lai HY; Tsai CH; Lai CC; Tang HJ; Chao CM
Front Microbiol; 2023; 14():1186669. PubMed ID: 37408643
[TBL] [Abstract][Full Text] [Related]
20. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
Wu H; Wang JT; Shiau YR; Wang HY; Lauderdale TL; Chang SC;
J Microbiol Immunol Infect; 2012 Apr; 45(2):120-6. PubMed ID: 22154599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
